Bicara Therapeutics Inc. Common Stock

BCAXNASDAQ • USD
9.55 USD
↘ 0.20 (2.05%)🟢LIVE (AS OF 02:24 PM EST)
🟢Market: OPEN

Bicara Therapeutics Inc. Common Stock (BCAX) is currently trading at $9.55. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest BCAX is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Nov 16, 2026.

Open?$9.83
High?$10.11
Low?$9.34
Prev. Close?$9.75
Volume?312.1K
Avg. Volume?1.8M
VWAP?$9.58
Rel. Volume?0.17x
Bid / Ask
Bid?$9.51 × 100
Ask?$9.53 × 100
Spread?$0.02
Midpoint?$9.52
Valuation & Ratios
Market Cap?647.3M
Shares Out?N/A
Float?43.2M
Float %?65.2%
P/E Ratio?N/A
P/B Ratio?1.58
EPS?-$3.32
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Employees
103
Market Cap
665.2M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2024-09-13
Address
116 HUNTINGTON AVENUE SUITE 703
BOSTON, MA 02116
Phone: 617-468-4219
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
99
Momentum?
23
Short Sent.?
51
Piotroski F-Score?0/9Weak
Altman Z-Score?5.28Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?22.84%Squeeze Risk
Short Interest?9.9M
Days to Cover?3.8
Free Float43.2M
Avg Daily Volume2.6M
Settlement Date2026-10-30
Financial Health
Current Ratio?8.81Strong
Quick Ratio?8.81Strong
Cash Ratio?1.60Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
85
1.58CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.4CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-53.8%WEAK▾
ROA?
S&P
3
-47.8%WEAK▾
Cash Flow & Enterprise
FCF?$-162750000
Enterprise Value?$565.3M
Fundamentals ratios updated end of day